Verdiva Bio

Private

GuildfordHealthcare & Life Scienceshttps://verdivabio.com/

Last Round

Series A

Jan 9, 2025

Total Funding Raised

$411M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Verdiva Bio is a biopharmaceutical company that develops next-generation therapies designed to help people living with obesity, cardiometabolic disorders, and related complications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

obesity treatmentoral GLP-1weight loss drugsGLP-1 receptor agonistGLP-1 drugsweight loss pillamylin agonistcardiometabolic therapiesclinical-stage biotechdrug in-licensingweight loss maintenanceoral peptide

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Verdiva Bio Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Verdiva Bio Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jan 9, 2025

View all Funding Rounds

Key People

Founding team and executive leadership

Tapan Maniar

Chief Business Officer Co-Founder

Founding Team

Khurem F.

Chief Executive Officer

Executive Team

Ashley Taylor

Chief Technology Officer

Executive Team

Verdiva Bio Investors

Notable investors and investment history

Investor	Rounds
Forbion Capital Partners	Series A
RA Capital Management	Series A
LYFE Capital	Series A
OrbiMed	Series A
Logos Capital	Series A
Lilly Asia Ventures	Series A
General Atlantic	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 24, 2026
Grew 17% QoQ, from 64 to 75 employees.
Apr 25, 2026
Grew 25% QoQ, from 59 to 74 employees.

View all signals

Verdiva Bio Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Verdiva Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Verdiva Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersGuildford

Employee Range75

Year Founded2024

Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.